Kasper P, Mueller L
Federal Institute for Drugs and Medical Devices, Berlin, Germany.
Carcinogenesis. 1996 Oct;17(10):2271-4. doi: 10.1093/carcin/17.10.2271.
Cyproterone acetate (CPA), a synthetic steroid hormone widely used as a human pharmaceutical, has recently been shown to induce unscheduled DNA synthesis (UDS) in vitro in primary cultures of rat and human hepatocytes. In the present study CPA was evaluated for its ability to initiate UDS in the liver of female rats in vivo by means of the in vivo/in vitro hepatocyte DNA repair test. Using the standard sampling time of 16 h after single oral dosing, a dose-related UDS response at >50 mg CPA/kg body wt was observed. In order to examine the time course of CPA-induced UDS, different sampling times (4, 16, 48, 72, 96 and 144 h) after a single oral administration of 100 mg CPA/kg body wt were used. Whereas no UDS was induced in liver cells isolated 4 h after treatment, continuous DNA repair activity was observed after 16 h, with a maximum effect of approximately 10 net nuclear grains on day 4 after dosing. After a post-application period of 6 days the net grain counts returned to near control level. In contrast to the data with CPA, DNA damage induced by the positive control compound 2-acetylaminofluorene was removed much faster, within 2 days after administration. The time course of UDS activity during the first 4 days after administration of CPA parallels the previously reported time course of DNA adduct formation. However, a subsequent decrease and final cessation of UDS on day 6 takes place, although significant levels of CPA-DNA adducts have been reported to occur at that time point in rat liver cells. Whereas the time-related onset of UDS is suggested to reflect the pharmacokinetics of the activation of CPA to DNA-reactive intermediates, it remains unclear why the excision repair of DNA adducts did not continue. In addition to DNA repair synthesis, CPA was also shown to clearly increase the incidence of S phase cells under the test conditions applied, confirming the known mitogenic potential of CPA in rat liver.
醋酸环丙孕酮(CPA)是一种广泛用作人类药物的合成甾体激素,最近已证明它能在大鼠和人类肝细胞的原代培养物中体外诱导非程序性DNA合成(UDS)。在本研究中,通过体内/体外肝细胞DNA修复试验评估了CPA在雌性大鼠肝脏中启动UDS的能力。采用单次口服给药后16小时的标准采样时间,观察到在CPA剂量>50mg/kg体重时出现剂量相关的UDS反应。为了研究CPA诱导UDS的时间进程,使用了单次口服100mg CPA/kg体重后不同的采样时间(4、16、48、72、96和144小时)。给药后4小时分离的肝细胞未诱导出UDS,而在16小时后观察到持续的DNA修复活性,给药后第4天最大效应约为10个净核颗粒。给药后6天,净颗粒计数恢复到接近对照水平。与CPA的数据相反,阳性对照化合物2-乙酰氨基芴诱导的DNA损伤在给药后2天内消除得更快。CPA给药后前4天UDS活性的时间进程与先前报道的DNA加合物形成的时间进程相似。然而,尽管据报道在该时间点大鼠肝细胞中存在显著水平的CPA-DNA加合物,但在第6天UDS随后下降并最终停止。虽然UDS与时间相关的起始被认为反映了CPA激活为DNA反应性中间体的药代动力学,但尚不清楚为什么DNA加合物的切除修复没有继续。除了DNA修复合成外,在应用的试验条件下,CPA还被证明能明显增加S期细胞的发生率,证实了CPA在大鼠肝脏中已知的促有丝分裂潜力。